144 related articles for article (PubMed ID: 34359562)
1. The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells.
Raab M; Rak M; Tesch R; Gasimli K; Becker S; Knapp S; Strebhardt K; Sanhaji M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359562
[TBL] [Abstract][Full Text] [Related]
2. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
Zhou J; Alfraidi A; Zhang S; Santiago-O'Farrill JM; Yerramreddy Reddy VK; Alsaadi A; Ahmed AA; Yang H; Liu J; Mao W; Wang Y; Takemori H; Vankayalapati H; Lu Z; Bast RC
Clin Cancer Res; 2017 Apr; 23(8):1945-1954. PubMed ID: 27678456
[No Abstract] [Full Text] [Related]
3. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
Ahmed AA; Lu Z; Jennings NB; Etemadmoghadam D; Capalbo L; Jacamo RO; Barbosa-Morais N; Le XF; ; Vivas-Mejia P; Lopez-Berestein G; Grandjean G; Bartholomeusz G; Liao W; Andreeff M; Bowtell D; Glover DM; Sood AK; Bast RC
Cancer Cell; 2010 Aug; 18(2):109-21. PubMed ID: 20708153
[TBL] [Abstract][Full Text] [Related]
4. A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin.
Fan D; Yang H; Mao W; Rask PJ; Pang L; Xu C; Vankayalapat H; Ahmed AA; Bast RC; Lu Z
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503955
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).
Liu Y; Gao S; Chen X; Liu M; Mao C; Fang X
Tumour Biol; 2016 Sep; 37(9):12231-12239. PubMed ID: 27236538
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
7. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.
Bon H; Wadhwa K; Schreiner A; Osborne M; Carroll T; Ramos-Montoya A; Ross-Adams H; Visser M; Hoffmann R; Ahmed AA; Neal DE; Mills IG
Mol Cancer Res; 2015 Apr; 13(4):620-635. PubMed ID: 25548099
[TBL] [Abstract][Full Text] [Related]
8. Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily.
Rak M; Tesch R; Berger LM; Shevchenko E; Raab M; Tjaden A; Zhubi R; Balourdas DI; Joerger AC; Poso A; Krämer A; Elson L; Lučić A; Kronenberger T; Hanke T; Strebhardt K; Sanhaji M; Knapp S
Eur J Med Chem; 2023 Jun; 254():115347. PubMed ID: 37094449
[TBL] [Abstract][Full Text] [Related]
9. Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis.
Hua Y; Yin H; Liu X; Xie J; Zhan W; Liang G; Shen Y
Adv Sci (Weinh); 2022 Aug; 9(22):e2202260. PubMed ID: 35618488
[TBL] [Abstract][Full Text] [Related]
10. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.
Miranda F; Mannion D; Liu S; Zheng Y; Mangala LS; Redondo C; Herrero-Gonzalez S; Xu R; Taylor C; Chedom DF; Carrami EM; Albukhari A; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Salah E; Abdul Azeez KR; Elkins JM; Campo L; Myers KA; Klotz D; Bivona S; Dhar S; Bast RC; Saya H; Choi HG; Gray NS; Fischer R; Kessler BM; Yau C; Sood AK; Motohara T; Knapp S; Ahmed AA
Cancer Cell; 2016 Aug; 30(2):273-289. PubMed ID: 27478041
[TBL] [Abstract][Full Text] [Related]
11. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.
Shi X; Yu X; Wang J; Bian S; Li Q; Fu F; Zou X; Zhang L; Bast RC; Lu Z; Guo L; Chen Y; Zhou J
Mol Oncol; 2022 Jul; 16(13):2558-2574. PubMed ID: 35278271
[TBL] [Abstract][Full Text] [Related]
12. Salt-Inducible Kinase 2: An Oncogenic Signal Transmitter and Potential Target for Cancer Therapy.
Chen F; Chen L; Qin Q; Sun X
Front Oncol; 2019; 9():18. PubMed ID: 30723708
[TBL] [Abstract][Full Text] [Related]
13. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound-Mediated Long-Circulating Nanopolymer Delivery of Therapeutic siRNA and Antisense MicroRNAs Leads to Enhanced Paclitaxel Sensitivity in Epithelial Ovarian Cancer Chemotherapy.
Liu Y; Long T; Zhang N; Qiao B; Yang Q; Luo Y; Cao J; Luo J; Yuan D; Sun Y; Li Y; Yang Z; Wang ZG
ACS Biomater Sci Eng; 2020 Jul; 6(7):4036-4050. PubMed ID: 33463352
[TBL] [Abstract][Full Text] [Related]
15. SIK2: A critical glucolipid metabolic reprogramming regulator and potential target in ovarian cancer.
Hu D; Du J; Xing Y; Cheng Y; He R; Liang X; Li H; Yang Y
J Obstet Gynaecol Res; 2023 Aug; 49(8):2000-2009. PubMed ID: 37317594
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of salt-inducible kinase 2 (SIK2) promotes immune injury by inhibiting the maturation of lymphocytes.
Zhu J; Li C; Wang P; Liu Y; Li Z; Chen Z; Zhang Y; Wang B; Li X; Yan Z; Liang X; Zhou S; Ao X; Zhu M; Zhou P; Gu Y
MedComm (2020); 2023 Oct; 4(5):e366. PubMed ID: 37706195
[TBL] [Abstract][Full Text] [Related]
17. Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation.
Shi M; Zhao M; Wang L; Liu K; Li P; Liu J; Cai X; Chen L; Xu D
Phys Chem Chem Phys; 2021 Jun; 23(23):13216-13227. PubMed ID: 34086021
[TBL] [Abstract][Full Text] [Related]
18. SIKs suppress tumor function and regulate drug resistance in breast cancer.
Xin L; Liu C; Liu Y; Mansel RE; Ruge F; Davies E; Jiang WG; Martin TA
Am J Cancer Res; 2021; 11(7):3537-3557. PubMed ID: 34354859
[TBL] [Abstract][Full Text] [Related]
19. Salt-inducible kinase 2 regulates TFEB and is required for autophagic flux in adipocytes.
Negoita F; Säll J; Morén B; Stenkula K; Göransson O
Biochem Biophys Res Commun; 2019 Jan; 508(3):775-779. PubMed ID: 30528240
[TBL] [Abstract][Full Text] [Related]
20. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
